Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juventas Therapeutics Inc.

www.juventasinc.com

Latest From Juventas Therapeutics Inc.

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific

Deal Watch: PDS And Edge Merge To Progress HPV-Linked Cancer Immunotherapy

Immunotherapy firms Edge and PDS announce planned merger, while Telix advances its prostate cancer strategy by acquiring ANMI. Kyowa Hakko Kirin is signed up to distribute GlaxoSmithKline's Phase III CKD-associated anemia product daprodustat in Japan.

Deals M & A

2015 REVIEW: Korea - Mega Deals, Biosimilars, Pricing Dominate News

2015 has been quite an eventful year for the South Korean pharma industry, and was marked by a string of major international licensing agreements that may be looked back on as a watershed in the industry’s attempts to shift to original R&D. If you missed any of the major news and analysis from South Korea during the year, here's your opportunity to check out PharmAsia News' view of the most important stories.

BioPharmaceutical South Korea

Korean Gene, Cell Therapies Edge Ahead In Challenging Environment

Despite the challenges in the sector, South Korean biotech companies are making substantial progress in the gene and cell therapy space, with several companies set to begin or already in late stage clinical trials at home and abroad, stepping gradually towards commercialization.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • AcelleRX Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Juventas Therapeutics Inc.
  • Senior Management
  • Rahul Aras, PhD, Pres. & CEO
    Marc Penn, MD, PhD, CMO
    Paul Resnick, MD, SVP, Bus. Dev.
  • Contact Info
  • Juventas Therapeutics Inc.
    Phone: (216) 273-4000
    3615 Superior Ave., Ste. 4403C
    Cleveland, OH 44114
    USA
UsernamePublicRestriction

Register